Gilead/FOCUS: Working Smarter to End HIV and HCV in the ED Through Screening and Linkage to Care

Sunday, September 29
5:00 – 5:45 pm
Location: Mandalay Bay Ballroom A

Speaker

James Daniel Moore, MD, MBA, FACEP; Kendra Jackson, MD; Jacob Manteuffel, MD, FACEP

Theater Information

The FOCUS program is the public health initiative of Gilead Sciences Inc. that supports access to screening and linkage to comprehensive preventative services and linkage to care for life-threatening diseases, such as blood-borne viruses (BBV), including HIV, HCV, HBV and soon, cancer. More than 1.1 million Americans currently live with HIV, 2.1 million with HCV, and nearly 1 million with HBV. These deadly diseases, however, are preventable. FOCUS supports healthcare organizations in developing and implementing best practices for institutional policy-driven screening, linkage to comprehensive prevention services for eligible individuals, and linkage to care following national and international public health guidelines. FOCUS partners aim to close the gap in health disparity and inequity for communities disproportionately impacted by high rates of morbidity, mortality, and late diagnosis of blood-borne viruses (BBV).

Supported by Gilead/FOCUS